Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06527872 · ClinicalTrials.gov registry record
Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN
A clinical trial of Lupus Nephritis, sponsored by GlaxoSmithKline.
- Recruiting
- Registry status
- 300
- Enrollment target
- 1
- Study location
NCT06527872: Recruiting study of Lupus Nephritis, sponsored by GlaxoSmithKline.
NCT06527872 is a study of Lupus Nephritis that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 300 participants, roughly in line with the 300-participant average among 30 other Lupus Nephritis trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06527872, a study of Lupus Nephritis, is actively recruiting participants, sponsored by GlaxoSmithKline.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the OBSErve-LN study is to assess the real-world use and effectiveness of belimumab in routine practice for the treatment of adults with active LN in multiple countries of interest. This study aims to provide the first long-term (up to 5 years) assessment of renal function preservation in belimumab treated participants.
Primary Outcome
Renal replacement therapy will involve participants requiring dialysis, kidney transplant, or those in end-stage kidney disease.
Conditions Studied
Interventions
- OTHER None (Observational study)
Study Locations (1)
North Carolina
- GSK Investigational Site - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2024-10-04 |
| Est. Completion | 2029-03-29 |
What NCT06527872 shows while recruiting
NCT06527872 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 300-participant average among 30 other Lupus Nephritis trials with a reported enrollment target.
The record links to 1 condition, with Lupus Nephritis appearing as the primary indexed condition, and to 1 intervention - of which None (Observational study) is the first listed.
NCT06527872 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT06527872 about?
NCT06527872 is a clinical study titled "Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN". The purpose of the OBSErve-LN study is to assess the real-world use and effectiveness of belimumab in routine practice for the treatment of adults with active LN in multiple countries of interest. This study aims to provide the first long-term (up to 5 years) assessment of renal function preservatio...
What is the current status of trial NCT06527872?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2024-10-04. Estimated completion is 2029-03-29.
What conditions does trial NCT06527872 study?
This clinical trial studies the following conditions: Lupus Nephritis.
What interventions are being tested in trial NCT06527872?
The interventions under investigation include: None (Observational study) (OTHER).
Who is sponsoring clinical trial NCT06527872?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06527872 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lupus Nephritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06527872's enrollment target sits among peer trials
300 7th of 30 higher than 24 of 30 other Lupus Nephritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lupus Nephritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
RECRUITING · Phase 2
-
The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study
RECRUITING · Phase 2
-
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
RECRUITING · Phase 3
-
VIBRANT: VIB4920 for Active Lupus Nephritis
RECRUITING · Phase 2
-
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
RECRUITING · Phase 1
-
Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI